Nouran Alwisi

Ms. Nouran Alwisi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
RARaneem Alsheikh
Raneem Alsheikh
FAFatima R. Alsharif
Fatima R. Alsharif
NANouran Alwisi
Nouran Alwisi
ZNZachariah Nazar
Zachariah Nazar
MSMohamed Ahmed Syed
Mohamed Ahmed Syed
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as a global health crisis in early 2020, leading to widespread morbidity and mortality. In Qatar, as of December 2024, the disease burden has reached over 500,000 cases and more than 600 deaths. While conventional treatments have evolved throughout the pandemic, the use of Complementary and Alternative Medicine (CAM), particularly herbal medicine, has also become prevalent. This study investigated the prevalence, reasons, uses, types, self-reported benefits, and sociodemographic determinants of utilising herbal medicine among COVID-19 patients in Qatar. A cross-sectional study was conducted among patients attending Qatar Primary Health Care Corporation (PHCC) clinics. Of the 10,000 SMS invitations that were sent, 882 survey responses were received from patients diagnosed with COVID-19 between 1 March 2020, and 30th April 2022. Following the exclusion of 31 participants due to missing data, sociodemographic data from 851 participants were analysed using logistic regression to assess predictors of herbal medicine use. Prevalence, patterns, types, and self-reported benefits were analysed using descriptive statistics. Of the 851 respondents included in the analysis, 440 (51.7%) reported herbal medicine use. Herbal medicine use was associated with better-perceived health outcomes. Women were more likely to use herbal medicine than men (OR = 1.90, 95%CI: 1.30-2.77, p = 0.001). The most used herbal remedies were ginger (n = 347), turmeric (n = 207), and garlic (n = 155). Family tradition (42%), the belief that herbs are natural (34.8%), and the desire to improve health and survival (31.1%) were the leading drivers of herbal medicine use. Herbal medicine use was prevalent (51.7%) during COVID-19 in Qatar, with a higher prevalence of use among women. This prevalence was driven by cultural beliefs and perceived health benefits. The study contributes insights to guide future research, policy, and practice toward safe and evidence-informed integration of herbal medicine in pandemic preparedness and broader healthcare strategies.

1 February 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
NANouran Alwisi
Nouran Alwisi
SASarah Aqel
Sarah Aqel
JNJanatul Naeim
Janatul Naeim
DADana Abdulla Al-Hashimi
Dana Abdulla Al-Hashimi
SHSamer El Hayek
Samer El Hayek
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality worldwide, with limited therapeutic progress due to challenges such as impermeability of the blood–brain barrier (BBB) and the multifactorial nature of secondary neurodegeneration. Nanoparticle-based platforms, owing to their tunable physicochemical properties, surface modifiability, and multifunctionality, have emerged as promising tools for both diagnosis and therapy. A wide range of inorganic, organic, and carbon-based nanoparticles has demonstrated improved imaging contrast, enhanced biosensing capabilities, and potential for targeted, real-time diagnostics. On the therapeutic front, nanoparticles have shown the ability to concentrate therapeutic agents at or near injury sites; however, achieving precise delivery remains a major challenge. Indeed, nanoparticle-based therapies are still limited by off-target accumulation in peripheral organs, incomplete BBB penetration, and heterogeneous tissue distribution. Addressing these barriers requires optimizing particle size, surface charge, ligand conjugation, and degradability to improve site-specific targeting and minimize systemic toxicity. In this review, we examine major classes of nanoparticles, including organic, inorganic, carbon-based, and biologically derived nanocarriers, and discuss the key physicochemical properties governing their interactions with the central nervous system. We evaluate their applications in TBI diagnosis, neuroimaging, and therapy, emphasizing the design principles influencing blood–brain barrier penetration, targeting specificity, biodistribution, and clearance. We further assess emerging nanoparticle-based strategies to improve site-specific delivery and mitigate secondary brain injury, and highlight key translational challenges and future clinical directions. Continued research into biodegradable, biomimetic, and environmentally sustainable synthesis methods is essential to advancing nanoparticle design and ensuring their safe and effective integration into the clinical management of TBI.

29 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AMAyman Musleh
Ayman Musleh
NANouran Alwisi
Nouran Alwisi
Hashem Abu SerhanHashem Abu Serhan
Hashem Abu Serhan
ATAhmad Amjed Toubasi
Ahmad Amjed Toubasi
LMLna Malkawi
Lna Malkawi
Saif Aldeen AlryalatSaif Aldeen Alryalat
Saif Aldeen Alryalat
Purpose: To compare the quality and efficiency of an AI-powered research automation (AIPRA) workflow with a conventional human-led workflow for producing a full systematic review manuscript on the same question. Methods: Two independent pipelines (human-led vs. AIPRA) each generated a complete manuscript addressing "What is the role of large language models in glaucoma diagnosis?". No protocols or templates were shared. Three blinded domain experts rated five domains on 5-point Likert scales. The primary endpoint was the overall quality of each workflow from query to final manuscript. Results: Mean total scores: human 74.7%, AIPRA 65.3%. The mean difference (AIPRA - Human) was -9.3% (95% CI, -18.8% to 0.0%), meeting the pre-specified non-inferiority criterion. Domain means were identical for query development (66.7% each); the human-led pipeline scored higher in screening, field selection, full-text extraction, and manuscript writing. AIPRA completed the workflow in approximately 2 hours versus about 1 month for the human pipeline (375x faster). Conclusion: AIPRA was non-inferior to human experts on overall quality while drastically reducing time to completion. Appropriate human oversight remains important, especially for screening and extraction tasks.

12 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NANouran Alwisi
Nouran Alwisi
RIRana Ismail
Rana Ismail
HAHissa Al-Kuwari
Hissa Al-Kuwari
KAKhalifa H. Al-Ansari
Khalifa H. Al-Ansari
MAMohammed A. Al-Matwi
Mohammed A. Al-Matwi
TCTawanda Chivese
Tawanda Chivese
Background/Objectives: Interleukin 12/23 inhibitors are a newer class of monoclonal antibodies used to induce and maintain remission for Crohn’s disease (CD), a chronic inflammatory bowel disease, when patients do not respond to conventional immunomodulatory drugs or first-line monoclonal antibody therapies. Although biologics are best administered intravenously, subcutaneous administration has been trialed, with mixed results. This research synthesized evidence on the efficacy and safety of subcutaneous compared to intravenous administration of interleukin 12/23 inhibitors for moderate to severe CD. Methods: In this systematic review and meta-analysis, we searched Cochrane, PubMed, SCOPUS, CINHAL, and preprint archives for randomized controlled trials (RCTs) that compared the efficacy and safety of subcutaneous to intravenous interleukin 12/23 inhibitors for the remission of CD. After study quality assessment, a meta-analysis was carried out using a bias-adjusted inverse variance heterogeneity model, heterogeneity was assessed using I2, and publication bias was performed using Doi plots. Evidence certainty was assessed using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). Results: Seven RCTs, with 2179 participants, all with moderate to severe CD, were included. After meta-analysis, subcutaneous compared to intravenous administration showed similar efficacy for the induction of remission (OR 0.77, 95%CI 0.53–1.12), with no-to-low heterogeneity (I2 = 0%, p = 0.97). For the maintenance of remission, only two studies had analyzable data, and they showed that subcutaneous interleukin 12/23 inhibitors were equal or better compared to intravenous administration. Further syntheses showed that subcutaneous compared to intravenous administration of interleukin 12/23 inhibitors had almost similar odds of adverse events (OR 0.91, 95%CI 0.63–1.32, I2 = 39%), serious adverse events (OR 0.97, 95%CI 0.61–1.53, I2 = 0%), and treatment discontinuation (OR 1.06, 95%CI 0.67–1.68, I2 = 0%). Conclusions: In individuals with moderate to severe CD, subcutaneous administration has similar efficacy for inducing remission with comparable safety. More RCTs are needed to confirm these findings.

14 October 2026 in Ibnosina Journal of Medicine and Biomedical Sciences
Verified
Journal Article
Open access
NANouran Alwisi
Nouran Alwisi
SMSidra Abdul Moqeeth
Sidra Abdul Moqeeth
RSRania Saad
Rania Saad
EAEman Almaraghi
Eman Almaraghi
SAShouq Alenazi
Shouq Alenazi
NANadia Alsharif
Nadia Alsharif
Celiac disease (CD) is a chronic autoimmune enteropathy triggered by gluten ingestion in genetically predisposed individuals. Beyond gastrointestinal (GI) symptoms, CD can present with diverse systemic complications, yet ophthalmic manifestations remain poorly studied. The Middle East is a high-prevalence region due to genetic susceptibility and wheat-based diets. This review aimed to evaluate CD research in the Middle East and North Africa (MENA) region, focusing on gastroenterological features and ophthalmic involvement. We conducted a systematic review of published studies on CD in MENA populations. PubMed, Scopus, Embase, and Web of Science were searched from inception to September 2025. Eligible studies included original data on CD diagnosis, clinical characteristics, and reported ophthalmic manifestations. Study quality was appraised independently by two reviewers using the Joanna Briggs Institute (JBI) critical appraisal tools. A total of 24 studies were included, encompassing both pediatric and adult populations across multiple MENA countries. Half of the studies (12/24) reported at least one ophthalmic manifestation. Reported ocular findings ranged from inflammatory and neuro-ophthalmic conditions, including uveitis, optic neuritis, optic neuropathy, and orbital myositis, to vascular and retinal abnormalities such as central retinal vein occlusion and pachychoroid spectrum disease. Dry eye disease was among the most frequently reported manifestations. Several studies also identified subclinical ocular changes, including alterations in choroidal thickness, retinal nerve fiber layer thickness, tear film parameters, and retinal microvascular perfusion. However, the available evidence was heterogeneous, predominantly derived from cross-sectional studies and isolated case reports, and varied considerably regarding diagnostic methods and ophthalmic assessment protocols. Ophthalmic abnormalities have been reported across several MENA populations with CD, involving the ocular surface, uveal tract, optic nerve, and retinal structures. However, the available evidence is insufficient to determine their true prevalence, establish causality, or confirm an increased risk compared with the general population. The predominance of studies from a limited number of countries, particularly Türkiye, further restricts regional generalizability. Future multicenter prospective studies using standardized CD diagnostic criteria and ophthalmic assessment protocols are needed to determine the prevalence and clinical significance of ocular involvement in CD.

19 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SHShahd Hamran
Shahd Hamran
LZLubna AbdulRahman Zar
Lubna AbdulRahman Zar
NANoora Alkorbi
Noora Alkorbi
AZAmna Zar
Amna Zar
FAFatima R. Alsharif
Fatima R. Alsharif
TCTawanda Chivese
Tawanda Chivese
Background: There is ongoing debate about the ideal blood glucose thresholds for the diagnosis of gestational diabetes mellitus (GDM), as individual randomized controlled trials (RCTs) comparing the lower International Association of Diabetes and Pregnancy Study Groups (IADPSG) blood glucose to criteria which use higher blood glucose thresholds have not been conclusive.Objectives: This meta-analysis compared lower to higher blood glucose thresholds for GDM diagnosis in terms of GDM prevalence and adverse maternal and neonatal health outcomes.Methods: We searched Cochrane CENTRAL, PubMed, Scopus, CINAHL, and preprint archives up to May 30, 2025, for RCTs that compared lower to higher glucose thresholds in the diagnosis of GDM in pregnancy. Endpoints were GDM prevalence and adverse pregnancy outcomes. After study quality assessment, meta-analysis was done using an inverse variance heterogeneity model, heterogeneity was assessed using I2, and publication bias by funnel plots. The quality effects model was used to synthesize evidence that was presented using forest plots.Results: Ten RCTs, comparing IADPSG to higher blood glucose thresholds, with a total of 88,311 pregnant women, were included. After meta-analysis, the lower glycemic criteria compared to the higher glycemic criteria was associated with almost double the prevalence of GDM diagnosis (13.7% vs 8.04%, respectively) and the odds of GDM diagnosis (OR = 1.87, 95%CI 1.47-2.37, I2 = 93.4%), with moderate certainty GRADE evidence. For adverse pregnancy outcomes, the lower glycemic criteria compared to the higher glycemic criteria were associated with a trend towards lower odds for gestational hypertension (OR 0.57, 95%CI 0.30-1.07), and neonatal hypoglycemia (OR 0.35, 95%CI 0.06-1.93, I2=88.2%). However, there were no differences between the glycemic thresholds for cesarean section (OR 0.94, 95% 0.78-1.13, I2= 0%). For all the outcomes, there was low certainty GRADE evidence.Conclusion: While the lower glycemic threshold results in close to double the prevalence of GDM and potentially higher workload for the healthcare system, this meta-analysis suggests that there may not be a difference in maternal and fetal outcomes when using lower vs higher thresholds in diagnosing GDM. However, the very low to low GRADE certainty suggests that further RCTs are needed to improve the certainty of evidence.